Driven by Innovation & Growth

Our mission is to promote innovation and growth through strengthened networks; advocacy; capital investment; talent attraction, development and retention; and advancing the next generation of leaders.

About Us

Virginia's Life Science Community By the Numbers

  • 1,451 Companies

    Life science companies in Virginia.

  • $8B Industry

    Life Science contributes $8B to Virginia's economy.

  • 26,545 People

    Employed by Life Science companies in Virginia.

  • $77,848 Average Wage

    Average earnings of life science workers in Virginia.

  • 1,197 Clinical trials

    Biopharmaceutical industry-sponsored trials in Virginia per year.

News

10/15/2024

Cerillo Introduces the Industry’s First Standardized Co-Culture System — Duet Revolutionizes Microbial Interaction and Isolation Studies

Cerillo, a leader in cellular analytics, announces the release of Duet, the first standardized co-culture system that allows researchers to explore microbial and cellular interactions in real time. Designed to address challenges in microbial research, Duet offers a novel approach to studying the dynamics between different microbial populations, enabling more precise, reproducible, and reliable results in fields ranging

10/15/2024

Serpin Pharma Secures $2 Million NCI Grant for Innovative Neuropathy Treatment

Serpin Pharma, a Virginia-based biopharmaceutical company, is proud to announce that it has been awarded a $2 million Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI). This grant will support the clinical development of SP16-3M, a groundbreaking peptide drug designed to prevent chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer

10/11/2024

FDA Approves Genentech’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved ItovebiTM (inavolisib), in combination with palbociclib (Ibrance®) and fulvestrant, for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast